40Hz: How a Single Frequency Is Reshaping the Treatment of Brain Disorders
DINGLIHUA"He came running from the lab to my office, tablet in hand — after 40Hz stimulation, amyloid protein levels in Alzheimer's mice had really dropped!" [1]
When MIT Professor Li-Huei Tsai recalled this moment, her voice still carried excitement. Her doctoral student, Hunter Iaccarino, had discovered in an optogenetics experiment that driving PV interneurons in the CA1 region of the mouse hippocampus at 40 hertz could significantly reduce the pathogenic Aβ protein. Even more surprising, without any implanted device, simply exposing mice to an LED light flickering at 40 times per second produced similar effects in the visual cortex.
This seemingly simple discovery kicked off a quiet revolution in neuroscience. Over the past decade, 40Hz sensory stimulation has moved from the laboratory to the clinic, continuously expanding the map of disease treatment.
I. What Is 40Hz Gamma Oscillation?
Our brains are constantly "firing." Billions of neurons fire synchronously at specific rhythms, generating brain waves at different frequencies. The 30–100 Hz band is called "gamma oscillation," with 40Hz at its core.
Imagine a symphony orchestra: pyramidal neurons play the melody, while PV interneurons act like a conductor, synchronizing the entire ensemble at 40 beats per second. The precise collaboration of this excitationinhibition loop forms the rhythmic foundation of higher cognitive functions.
Interestingly, gamma oscillations are abnormal in many neuropsychiatric disorders, including Alzheimer's disease and schizophrenia. So, can we externally "beat time" for the brain to bring its disordered rhythm back on track?
II. Alzheimer's Disease: Three Nature/Cell Papers in a Decade
1. 2016 – Non- invasive light stimulation reduces protein levels
Iaccarino et al. published a landmark study in Nature. Exposing Alzheimer's model mice to an LED light flickering at 40 times per second for just one hour significantly reduced Aβ protein in the visual cortex. [2]
More critically, the mechanism was revealed — microglia (the brain's "cleanup cells") were activated. They transformed from a resting "branched" morphology into an active "amoeboid" shape, surrounding and engulfing the pathogenic proteins. This was the first causal demonstration linking neural oscillations to neurodegeneration and opened an entirely new direction for noninvasive sensory stimulation therapy for neurodegenerative diseases.
2. 2019 – Combined light and sound, better efficacy
The Tsai lab published GENUS (Gamma Entrainment Using Sensory Stimuli) in Cell: combined 40Hz light and 40Hz sound stimulation covered broader brain regions and produced more significant pathological improvements than either modality alone. [3]
A concurrent study in Neuron further confirmed that weeks of continuous stimulation not only reduced Aβ and tau deposits but also protected neurons from degeneration and maintained synaptic density — direct evidence of a "neuroprotective" effect of 40Hz intervention.
3. 2024 – The "clearance pathway" is discovered
Where did the reduced pathogenic proteins go? Murdock et al. answered that question in a 2024 Nature paper: the glymphatic system.
The brain has a waste- clearance network analogous to the lymphatic system. 40Hz multisensory stimulation robustly activated this "sewer system": it enhanced cerebrospinal fluid inflow and interstitial fluid outflow, and dilated meningeal lymphatic vessels. When key proteins AQP4 or VIP neurons were genetically or pharmacologically blocked, the clearance effect vanished — precisely locking down this mechanistic pathway. [4]
4. 2025 – First long- term human data
Chan et al. published the first two- year open- label extension study results in Alzheimer's & Dementia. Five mild AD patients received one hour of daily 40Hz audiovisual stimulation; no serious adverse events occurred throughout.
Three of these patients with lateonset AD (LOAD) maintained strong EEG gamma entrainment, and their cognitive decline was significantly slower than agematched controls from large databases. Even more encouraging, blood biomarker pTau217 — a core AD marker — decreased by up to 47% in two patients. [5]
[Note: This study involved only 5 participants, was unblinded, and is exploratory. Yet these signals lay the groundwork for larger randomized controlled trials.]
III. Beyond Dementia: New Hope for Epilepsy and Pain
1. Epilepsy – A counterintuitive anticonvulsant effect
Epilepsy is fundamentally excessive synchronous firing of neurons. Since 40Hz enhances synchrony, could it worsen seizures? A 2025 Nature Communications study gave a counterintuitive answer: chronic 40Hz light flicker actually reduced seizure severity and susceptibility.
Wang et al. showed that this effect depends on a precise visual pathway: ONOFF directionselective retinal ganglion cells → shell of the dorsal lateral geniculate nucleus (dLGN) → fastspiking PV interneurons in layer 2/3 of visual cortex V1. After six weeks of stimulation, seizures were markedly reduced, and neuronal loss and gliosis were significantly attenuated.
2. Chronic pain – Using light to "erase" pain memory
An even more surprising finding was reported in Cell Research in 2026: 40Hz flickering light effectively relieved both inflammatory and neuropathic pain, outperforming other stimulation frequencies.
Chen et al. identified the retinacentral amygdala (RetinaCeA) pathway as the key analgesic circuit. 40Hz light stimulation elevated adenosine levels in this brain region, suppressing nociceptive responses via A2A receptors. Remarkably, it not only alleviated ongoing pain but also "erased" established hyperalgesic memory — as if formatting the brain's pain circuitry.
IV. How Does It Actually Work in the Brain?
Synthesizing current research, the mechanisms of 40Hz neuromodulation show a clear layered hierarchy: [6]
V. How Far Are We from Clinical Use?
40Hz stimulation is moving from basic research toward clinical application. Several companies (e.g., Cognito Therapeutics) have developed wearable devices, and larger trials are ongoing.
But challenges remain. A 2026 Experimental Neurology review by Cai et al. systematically outlined key issues:
1.Current trials have small sample sizes; largescale, randomized, doubleblind controlled studies are lacking.
2.Stimulation parameters are highly heterogeneous; an optimal protocol has not been established.
3.Large individual variability calls for future "personalized tuning."
4.Longterm safety still needs monitoring.
Future directions include delivering stimulation during sleep (the glymphatic system is more active during sleep), developing "invisible flicker" technology to improve adherence, and exploring synergistic combinations with drugs or immunotherapy.
Ten years ago, a sprint down an MIT corridor changed the course of a research field. Today, 40Hz has grown from a curious laboratory finding into a potential therapeutic tool spanning Alzheimer's disease, epilepsy, chronic pain, and beyond.
It is noninvasive, safe, and lowcost — perhaps the missing piece in the therapeutic landscape for neurological diseases in an aging era. Though there is still a long road from scientific discovery to routine clinical use, this light has already entered reality.
[1] Hunter F. Iaccarino, Annabelle C. Singer, Anthony J. Martorell, et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 540, pages230–235 (2016)
https://www.nature.com/articles/nature20587
[2] Anthony J. Martorell, Abigail L. Paulson, Ho-Jun Suk , et al. Multi-sensory Gamma Stimulation Ameliorates Alzheimer’s-Associated Pathology and Improves Cognition. Cell. Volume 177, Issue 2p256-271.e22April 04, 2019
https://www.cell.com/cell/fulltext/S0092-8674(19)30163-1
[3] Chinnakkaruppan Adaikkan,Steven J. Middleton, et al. Gamma Entrainment Binds Higher-Order Brain Regions and Offers Neuroprotection. Neuron. Volume 102, Issue 5p929-943.e8June 05, 2019
https://www.cell.com/neuron/fulltext/S0896-6273(19)30346-0
[4] Mitchell H. Murdock, Cheng-Yi Yang, Na Sun，et al. Multisensory gamma stimulation promotes glymphatic clearance of amyloid. Nature. 627, pages149–156 (2024)
https://www.nature.com/articles/s41586-024-07132-6
[5] Diane Chan, Gabrielle de Weck, Brennan L.et al. Gamma sensory stimulation in mild Alzheimer's dementia: An open-label extension study. Alzheimer's & Dementia. 25 October 2025
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70792
[6]Yuang Cai a, Jiajun Kang，et al. From mechanisms to clinical applications: Advances in 40 Hz gamma oscillation modulation for the treatment of neurological disorders. Sciencedirect. Volume 401, July 2026, 115741
https://www.sciencedirect.com/science/article/abs/pii/S0014488626001044
